Semaglutide

STEP-HFpEF

A prespecified secondary analysis of the pooled STEP-HFpEF and STEP-HFpEF DM trials shows once-weekly semaglutide 2.4 mg lowered NT-proBNP and improved symptoms in obesity-related HFpEF. PICO summary and expert commentary.

Semaglutide and NAION Risk: Danish Registry Study Shows Doubled Incidence

In patients with type 2 diabetes (T2D), once-weekly semaglutide significantly increased the risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) compared to non-exposure, doubling the five-year hazard ratio (HR), though it was associated with improved glycaemic control and other cardiometabolic benefits.

Oral Semaglutide Phase 1 Trial

STEP 1-4 Trials: Semaglutide 2.4 mg for Weight Loss and Quality of Life

SELECT Trial: Long-Term Weight Loss with Semaglutide in Cardiovascular Disease

SELECT Kidney Outcomes

STEP-HFpEF: Semaglutide Improves NYHA Functional Class in Obesity-Related HFpEF

Semaglutide and Kidney Outcomes

STEP-HFpEF NT-proBNP Analysis: Greater Benefit with Higher Baseline Cardiac Stress

SURPASS-2